article thumbnail

Scrub-a-Dub-Dub: FTC is Cleansing the Orange Book of Device Patents

FDA Law Blog: Biosimilars

Koblitz — As we have noted for the last year or so, the FTC has been on a mission to clean up the Orange Book by removing what it deems to be “improper” patents. FTC, deep in its foray into the Orange Book, filed an Amicus Brief in the case arguing that the patents do not claim any FDA-approved drug. And on X (R.I.P.

FDA 113
article thumbnail

Announcing Our First Book: Origins

Codon

Our first book, Origins , is now available for purchase. The book is an ode to scientific progress, and the articles within tell stories about everything from the origins of synthetic biology to the discovery of an antimalarial drug in China and the invention of the micropipette. Purchase the Book You can read that here.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Legislative Proposals to Tackle Improper Pharmaceutical Patents in the Orange Book

Drug Patent Watch

A recent article published in Health Affairs, delves into the Federal Trade Commission’s (FTC) concerns regarding the inclusion of improper patents in the FDA’s Orange Book by pharmaceutical manufacturers.

article thumbnail

Insights into Shifting Dynamics: Orange Book and Biologic PTAB Trends

Drug Patent Watch

Brinckerhoff discusses trends in Inter Partes Review (IPR) and Post Grant Review (PGR) proceedings involving Orange Book and biologic patents, based… The post Insights into Shifting Dynamics: Orange Book and Biologic PTAB Trends appeared first on DrugPatentWatch - Make Better Decisions.

95
article thumbnail

FTC Continues to Rage Against Device Patent Listings in the Orange Book

FDA Law Blog: Biosimilars

Koblitz — The FTC appears to be on a mission to cleanse the Orange Book of patents it deems improperly listed. For the second time in recent years, the FTC has filed an Amicus Brief explaining exactly which patents should not be in the Orange Book.

FDA 57
article thumbnail

A New Book on Hatch-Waxman – Breaking the Medicine Monopolies: Reflections of a Generic Drug Pioneer

FDA Law Blog: Biosimilars

Throughout his illustrious career, Al has been engaged with Hatch-Waxman, even authoring one of the earliest papers providing an account of the law: “ Special Patent Provisions for Pharmaceuticals: Have They Outlived Their Usefulness? ” In his new book, “Breaking the Medicine Monopolies: Reflections of a Generic Drug Pioneer,” which will be released (..)

Drugs 57
article thumbnail

America's Pediatricians Want You to Read a Book With Your Child

Drugs.com

MONDAY, Sept. 30, 2024 -- Read to your little ones.That's the American Academy of Pediatrics' (AAP) prescription for fostering loving, nurturing relationships during early infancy and early childhood -- a time of critical brain development."Reading.

98